T cells from Vav1AA/AA mice also show a proliferative defect when injected into MHC-mismatched recipient animals in a mechanistic GvH mouse model (Fig. 3). The

total number of Vav1AA/AA T cells after 3 days was strongly reduced compared to WT T cells, and 18% of the cells did not divide at all. Interestingly, the majority of Vav1AA/AA T cells reached 6 division cycles, showing that there was no complete block in proliferation. Rather, Vav1AA/AA T cells seemed to have divided more slowly compared to WT T cells, which led to the reduced total numbers of cells. This is in contrast to T cells treated with the strong immunosuppressant CsA, where the majority of T cells did not divide at all. However, in a previous study, T cells from Vav1−/− mice also did not show a complete block in proliferation but a similar delay in proliferation, which was enhanced in T cells from mice deficient in both DAPT supplier Vav1 and Vav2 [23]. These findings suggest that disruption of Vav1 function only partially affects the TCR-induced proliferative signals which can be overcome by a stronger costimulatory environment in vivo. Vav1 GEF activity seems to be important for the Vav1-mediated proliferative response, as Vav1 GEF inactivation and total Vav1 deficiency have comparable effects. CsA, however, might affect Vav-independent TCR-induced signals INK 128 ic50 and also different stimuli

in addition to TCR engagement such as cytokines and costimulatory signals, which also contribute to T cell proliferation [28]. Furthermore, CsA has effects on other cell types and tissues resulting in strong general immunosuppression, which may explain the stronger response compared to Vav1 inactivation. Vav1AA/AA mice show prolonged cardiac allograft survival with a mean survival time of 22 days compared to WT animals which reject the allograft after 7 days (Fig. 4). These findings confirm

the previously observed central role for Vav1 in allograft rejection [23]. Vav1AA/AA as well as Vav1−/− mice have reduced numbers of peripheral T cells due to a defect in thymic development [20], and we cannot exclude a partial effect of this reduction on allograft survival. However, Vav1AA/AA T cells showed a strong defect in allogeneic T cell proliferation and activation in vitro and in vivo when Rebamipide equal numbers of T cells were used, indicating that the prolonged allograft survival in Vav1AA/AA mice is likely to be caused by defective T cell activation. However, to fully confirm these findings, inducible genetic systems or specific Vav1 inhibitors will be needed. Graft survival in Vav1AA/AA mice is not as pronounced as in Vav1−/− mice which lack the whole Vav1 protein, indicating that the GEF function of Vav1 affects only part of the processes mediating rejection [23]. This could also account for the high variation in allograft survival time observed for the Vav1AA/AA mice.